INS and COVID-19: Patients who are overweight, obese, or have metabolic disorders tend to have different serum levels of adipokines and EB (cortisol, C-peptide, GLP-1, insulin, and PYY) compared to those without metabolic comorbidities, which could be associated with poor outcomes in patients with COVID-19.